这家丹麦药企将司美格鲁肽全系列药物月均统一定价为675美元，降幅高达50%。其美国竞争对手礼来 (LLY.US)的同类减肥药物Zepbound，目前官方定价为1086.37美元/月。 智通财经APP获悉，诺和诺德(NVO.US)计划于明年大幅下调旗下两款重磅药物Wegovy和Ozempic的美 国官方定价，以在肥胖症治疗市场争夺更大份额。 目前，诺和诺德正在价格方面多措并举，以提升在肥胖症领域的竞争力。Millar曾任职于联合健康 (UNH.US)旗下药品福利管理机构Optum Rx，是美国定价策略方面的专家。 新价格将于明年1月1日生效。Millar表示，公司需要现在宣布降价，以便让付款方有时间应对明年的变 化。 他指出，此次调整对高免赔额保险人群影响尤为明显——这类保单的自付费用与官方定价高度挂钩;按 药品定价比例付费的共付保险患者，同样将受益。 据KFF的雇主健康福利调查，去年约三分之一参保职工选择了高免赔额医保搭配个人健康储蓄账户方 案;调查同时显示，不到一半的大型企业为Wegovy这类GLP-1减重药物提供医保报销。 此次降价针对的是批发采购成本，这一公开标价并不反映美国市场复杂的返利体系。在商业保 ...

Core Insights - The price war for weight loss drugs, specifically the imported medications Semaglutide and Tirzepatide, has begun earlier and more aggressively than market expectations [1] Pricing Changes - Starting January 1, the price of Eli Lilly's Tirzepatide injection (Mounjaro) has significantly decreased after being included in the medical insurance, with the following price reductions: - The initial dosage of 2.5mg*4 doses dropped from 1758 yuan to 324.12 yuan - The main specification of 5mg*4 doses fell from 2758 yuan to 551 yuan - The highest dosage of 10mg*4 doses decreased from 4758 yuan to 936.70 yuan - All reductions exceed 80% [1] - Novo Nordisk's Semaglutide injection (Ozempic) also experienced substantial price cuts: - The initial dosage of 0.25mg*4 doses decreased from 1264.9 yuan to 230.84 yuan, a reduction of 82% - The 2.4mg*4 doses fell from 2463 yuan to 1284.36 yuan, a reduction of 48% [1] Market Dynamics - The price reductions affect the three major players in the weight loss drug sector and cover both hospital and e-commerce platforms, indicating a significant price war in the weight loss medication market [1]

Core Insights - The price of weight loss drugs has significantly decreased within a short period, indicating a price war in the market [1][2][3] - Compliance risks are emerging alongside the price competition, with concerns about misleading marketing and prescription practices [1][7][8] Price Trends - In late December 2022, major weight loss drugs like Semaglutide and Tirzepatide saw substantial price reductions on various e-commerce platforms [2] - Recently, Tirzepatide's price on Meituan dropped by 40 yuan, while Semaglutide's price remains between 300-400 yuan, significantly lower than six months ago [5] - Domestic weight loss drug Masitide from Innovent Biologics has also begun to lower prices, with its 0.5ml:2mg version dropping from 540 yuan to 399 yuan [5][6] Compliance Issues - There are serious compliance concerns regarding the marketing of GLP-1 drugs, which are primarily approved for diabetes treatment but are being promoted for weight loss [7][8] - Marketing phrases like "not losing weight, money back" are being used, which may violate advertising laws [7] - The prescription process for these drugs on e-commerce platforms has been criticized for being too lenient, allowing non-diabetic patients to obtain prescriptions easily [10][11] Regulatory Landscape - The National Medical Products Administration has proposed guidelines for online prescription drug sales, emphasizing the need for compliance in prescription verification and marketing practices [11][13] - There is ongoing discussion about integrating online prescription drugs into the medical insurance payment system, which could enhance accessibility but also poses regulatory challenges [13][15] - Experts suggest that clear regulations are needed to define the responsibilities of platforms, pharmaceutical companies, and medical institutions in the online prescription drug market [15]

Core Viewpoint - Eli Lilly has lowered the entry price of its weight loss drug Zepbound in response to increasing competition from Novo Nordisk, marking a significant move in the ongoing price war between the two companies in the lucrative obesity treatment market [1][2] Pricing Strategy - Starting from this week, the cash price for the lowest dose of Zepbound will be $299 per month, a reduction of approximately $50 from the previous price [1] - The price for the next higher dose will decrease to $399 per month, down about 20% from the prior cash price [1] - The highest dose remains unchanged at $499 per month [1] Competitive Landscape - The price reduction is part of a broader competitive strategy between Eli Lilly and Novo Nordisk, which has also recently lowered its cash prices for its drugs Ozempic and Wegovy [1][2] - Novo Nordisk's entry-level price for Ozempic and Wegovy is $199 for the first two months, increasing to $349 thereafter [1] Market Context - Analysts project that the global obesity treatment market will reach $100 billion by the end of this decade, highlighting the significant financial stakes involved [2] - Both companies are exploring competitive advantages, including agreements with U.S. drug benefit managers and discounts for cash-paying customers [2] Regulatory Environment - The Biden administration has announced negotiations that could lead to discounts of up to 71% for Ozempic and Wegovy for federal Medicare patients, effective in 2027 [2] - Eli Lilly and Novo Nordisk have agreed to lower their prices in the U.S. as part of a government agreement that will also apply to cash-paying customers, with changes set to take effect in 2026 [2]